EULAR recommendations for a core data set for pregnancy registries in rheumatology

Yvette Meissner 1, Rebecca Fischer-Betz 2, Laura Andreoli 3,4, Nathalie Costedoat-Chalumeau 5,6, Diederik De Cock 7, Radboud J E M Dolhain 8, Frauke Forger 9, Doreen Goll 10, Anna Molto 11,12, Catherine Nelson-Piercy 13,14, Rebecca Özdemir 15, Luigi Raio 16, Sebastian Cruz Rodríguez-García 17, Savino Sciascia 18, Marianne Wallenius 19,20, Astrid Zbinden 9, Angela Zink 1, Anja Strangfeld 1

ABSTRACT

Background and objective There is an urgent need for robust data on the trajectories and outcomes of pregnancies in women with inflammatory rheumatic diseases (IRD). In particular when rare outcomes or rare diseases are to be investigated, collaborative approaches are required. However, joint data analyses are often limited by the heterogeneity of the different data sources. To facilitate future research collaboration, a European League Against Rheumatism (EULAR) Task Force defined a core data set with a minimum of items to be collected by pregnancy registries in rheumatology covering the period of pregnancy and the 28-day neonatal phase in women with any underlying IRD.

Methods A stepwise process included a two-round Delphi survey and a face-to-face meeting to achieve consensus about relevant items.

Results A total of 64 multidisciplinary stakeholders from 14 different countries participated in the two rounds of the Delphi process. During the following face-to-face meeting of the EULAR Task Force, consensus was reached on 51 main items covering ‘maternal information’, ‘pregnancy’ and ‘treatment’. Generic instruments for assessment are recommended for every item. Furthermore, for the five most frequent IRDs rheumatoid arthritis, spondyloarthritis, juvenile idiopathic arthritis, systemic lupus erythematosus and other connective tissue diseases, disease-specific laboratory markers and disease activity measurements are proposed.

Conclusion This is the first consensus-based core data set for prospective pregnancy registries in rheumatology. Its purpose is to stimulate and facilitate multinational collaborations that aim to increase the knowledge about pregnancy course and safety of treatment in women with IRDs during pregnancy.

INTRODUCTION

In recent years, several European pregnancy registries have been established in rheumatology to prospectively collect and analyse data on pregnant women with different inflammatory rheumatic diseases (IRD). However, certain research issues, for example, studying the pregnancy course in rare diseases, require even larger study populations, often exceeding the number of patients available in each registry, making collaborative analyses desirable. The European League Against Rheumatism (EULAR) Task Force on antirheumatic drugs during pregnancy and lactation also highlighted the need for collaboration to collate data on newer medications.

Combined analysis of data from different sources requires a certain degree of homogeneity among the data collected. A recent comprehensive survey of four registries working together in the European Network of Pregnancy Registries in Rheumatology (EuNeP) showed similar study designs in terms of prospective data collection, inclusion of patients with IRD before or during early pregnancy, and reporting of data in each trimester of pregnancy. However, major differences were found in the details of data collection, for example, in the instruments used to measure disease activity. As highlighted by other initiatives in rheumatology, harmonising and standardising items and their measurement across studies is critical to facilitate collaborative research.

A EULAR Task Force was therefore convened to define a core data set for registries and observational studies that prospectively collect information about pregnant women with IRD including the neonatal phase (four weeks post partum). The core set was developed to encompass a minimum of standardised items to be collected paving the way for multinational collaborations.

METHODS

An iterative process according to EULAR standardised operating procedures was applied to develop the core set. The Task Force comprised a convenor (AS) and coconvenor (RFB), a methodologist (AZi), a fellow (YM), eight Task Force members (LA, NC-C, RJEKD, FF, AM, CN-P, LR, MW), three EMEUNET members (DJD, SCRG, SS), two patient research partners (DG, RO) and one health professional (AZb). The scope and core areas of the core set according to the Core Outcome Set-STAndards for Development recommendations were defined by consensus. A study protocol was developed and circulated among the Task Force. The flow chart gives an overview of all steps taken during the project (figure 1).

Generation of items

Items estimated relevant to be included in the core set were compiled (1) by a systematic literature
Recommendation

- Literature review: 118 items
- Survey (pregnancy registers): 117 items
- Survey (patient partners): 8 items

**Compilation of initial DATA ITEM LIST** 143 data items

Delphi round 1 143 data items

- Consensus in 77 data items
- Consensus out 0 data items
- Equivocal 66 data items

Delphi round 2 148 data items

- Consensus in 89 data items
- Consensus out 0 data items
- Equivocal 59 data items

New proposals 5 data items

Final voting 157 data items

- Exclusion 71 data items
- Inclusion 78 data items

**51 main data items**

**Figure 1** Flow chart of the development and consensus process for the core data set. EULAR, European League Against Rheumatism; EuNeP, European Network of Pregnancy Registries in Rheumatology.

search (see online supplemental for details) and underpinned (2) by an inventory of items collected by registries participating in EuNeP2 and (3) from results of a survey among three EuNeP patient representatives regarding their needs during pregnancy. An initial list of items was created by deleting duplicates, grouping similar items and refinement. Consequently, every item on the list was assigned to its respective core area.

**Consensus process, outcome scoring and consensus definition**

The importance of each item for the final core set was judged by a stepwise consensus process encompassing a two-round Delphi survey and a final vote. In addition to the members of the EULAR Task Force (except the fellow), additional experts in the field of pregnancy and rheumatology from different European countries were invited to participate during the Delphi votes. In particular, up to five clinicians involved in each of the four registries of the EuNeP collaboration, as well as clinical researchers and experts in the areas of rheumatology, epidemiology, obstetrics, gynaecology, internal medicine as well as other health professionals were directly invited by email. The Delphi process was performed using the online tool ‘Delphi Manager’ (http://www.comet-initiative.org/delphimanager). This tool ensures the anonymity of all participants and adherence to the single steps of the Delphi process.

Participants were asked to rate the importance of each item to be included in a core set for pregnancy registries in rheumatology using the Grading of Recommendations, Assessment, Development and Evaluations scale9 from 1 to 9 (1–3=not important, 4–6=important but not critical, 7–9=critical/very important). The participants had the option to indicate an item as ‘unable to score’ if necessary and could give comments on each item. Additionally, adding comments at the end of the survey was also possible. The scores of every participant were anonymous throughout the survey. Finally, participants were asked to suggest additional items that were not listed in the initial item list. All suggested, additional items were thoroughly reviewed by nine
members of the Task Force, and eligible items were added in Delphi round 2.

Every participant of Delphi round 1 was invited to rescore the items in round 2 taking total scoring results (given as percentages of all participants scoring 1–9) and their own scores of round 1 into account. Each Delphi round had to be completed within 3 weeks. After completion of both Delphi rounds, scores of round 2 were summarised and assigned to one of the three pre-specified consensus definitions comprising ‘consensus in’, ‘consensus out’ and ‘equivocal’ (table 1) according to OMERACT recommendations.

All items that neither reached ‘consensus in’ nor ‘consensus out’ were defined as equivocal and needed a final voting. The final voting took place at a face-to-face consensus meeting of the EULAR Task Force. During this meeting the items were discussed and finally voted on. The voting was conducted via a mobile phone based electronic voting system (www.tedme.com). Items that reached a majority of votes were included into the core set, those with a majority of negative votes were excluded. Furthermore, the Task Force refined the core set and discussed all items with ‘consensus-in’ status regarding their applicability in a core set and usefulness for research purposes. Of note, the way of assessment of each item and their exact definition was not subject of the Delphi voting.

Since the core set is supposed to cover items important for a variety of IRDs, it was strengthened during the Task Force meeting to also define additional, disease-specific items covering laboratory markers as well as disease activity and damage measurements. All relevant items were summarised by the Task Force and the importance of each item for the respective disease was rated in a written non-anonymous voting. Each Task Force member made her/his decisions according to her/his expertise in the field. Items that reached a majority of positive votes were included in the additional item list. The additional items were defined for the most prevalent IRDs in women of reproductive age: rheumatoid arthritis, spondyloarthritis, juvenile idiopathic arthritis, systemic lupus erythematosus and other connective tissue diseases. Other connective tissue diseases include Sjögren’s syndrome, undifferentiated connective tissue disease, scleroderma, myositis and mixed connective tissue diseases.

Data analysis
For both Delphi rounds, mean and SD, median, minimum and maximum as well as the distribution of scores within the three consensus categories were calculated using SAS software V9.4.

RESULTS
Stakeholders
In total, 73 experts received an email invitation to participate in the Delphi vote, including 17 members of the EULAR Task Force. Of all experts invited, 65 (89%) participated in round 1 and 64 (88%) in round 2. About two-thirds of the experts (69%) participating in both Delphi rounds were women. The majority of participants (81%) had 10 years or more work experience, 14% were working for at least 5 and up to 10 years, and 5% indicated 5 years or less work experience. A total of 84% were rheumatologists, 5% each were obstetricians and epidemiologists, 3% each patients and midwives. Experts from 14 different European countries were represented (online supplemental table 1 shows country distribution).

Definition of core areas
Three core areas were defined as ‘maternal information’, ‘pregnancy’ and ‘treatment’ (figure 2). Maternal information includes the core domains demographics and risk behaviours, disease characteristics of the underlying IRD and prevalent comorbidities. The core area ‘pregnancy’ encompasses information on obstetrical history, the course, outcomes and delivery of the current pregnancy and outcomes of the neonate. In the core area ‘treatment’, medical treatment within 12 months prior to conception, the treatment of the IRD during pregnancy and post partum as well as the use of other treatments during pregnancy are subsumed.

Results of the consensus process for non-disease specific items
A total of 143 items were up for voting in Delphi round 1. Of those, 77 items were voted as critically important by at least 70% of the participants. Another 69 new items were suggested to be added to the following Delphi round. All of them were thoroughly reviewed by eight members of the Task Force, and five items were considered as new and relevant for the item list (online supplemental table 2). They encompass gestational age at birth in previous pregnancies, number of previous miscarriages, neonatal infections, the use of non-steroidal anti-inflammatory drugs (NSAIDs) and start and stop dates of NSAID treatment.

With the newly suggested items of round 1, Delphi round 2 included a total of 148 items. Of those, 89 items reached consensus in during the vote, none of the items reached consensus out and 59 items were rated as equivocal and were therefore neither in nor excluded (figure 1, online supplemental table 3).

At a face to face meeting of the Task Force members (n=12), all equivocal items were voted on. Task Force members who were unable to attend the meeting (n=5) received the voting list in advance and their votes were incorporated into the decision process. Additionally, participants of the meeting discussed and evaluated all items of the final core set with respect to the importance of the item for research purposes and redundancy. All decisions are explained in detail in online supplemental table 3. In order to make the extensive list of the resulting 78 included items more comprehensible for the user, the items were consequently defined as either main item (n=51) or operationalizing item (n=27). Items of the final core set are presented in table 2.

Furthermore, the way of assessment/operationalisation for each

Table 1 Consensus definitions

| Decision       | Definition                                           | Explanation                                      |
|----------------|------------------------------------------------------|-------------------------------------------------|
| Delphi round 1/2 |                                                      |                                                 |
| Consensus in   | >70% of the participants rated the item as critically important for the core data set (scores 7–9) | Item will be included into the final core data set |
| Consensus out  | >70% of the participants rated the item as not important for the core data set (scores 1–3) | Item will be excluded from the final core data set |
| Equivocal      | All items that are neither in the consensus-in nor in the consensus-out group | No consensus was reached for the respective item. Final decision at the consensus meeting |
| Face-to-face consensus meeting |                                                      |                                                 |
| Consensus in   | Simple majority (>50% of votes) | Item will be included into the final core data set |
| Consensus out  | Simple majority (>50% of votes) | Item will be excluded from the final core data set |

Meissner Y, et al. Ann Rheum Dis 2020;0:1–8. doi:10.1136/annrheumdis-2020-218356
main item including instruments and categories where appropriate was defined and summarised in the online supplemental table 4.

Recommendations for disease-specific items
The recommended laboratory markers and disease activity measurements found to be relevant by the Task Force for the five IRDs rheumatoid arthritis, spondyloarthritis, juvenile idiopathic arthritis, systemic lupus erythematosus and other connective tissue diseases are presented in table 3. It is recommended for registers to collect the single components of a summary score rather than only the score, for example, C reactive protein (CRP), 28 swollen and tender joint count (SJC, TJC) rather than collecting only the disease activity score Disease Activity Score based on 28 tender and swollen joints and C reactive protein.

Methodological considerations
Pregnancy registries are prospective observational cohort studies that collect essential clinical information related to pregnancy in order to improve the safety of mother and child. The items defined with this core set refer to women with IRD and cover the pregnancy and the neonatal phase. The Task Force recommends that patients should be enrolled at the earliest possible point in time during pregnancy. Data should ideally be collected once every trimester and during the neonatal phase (within 28 days after birth). Besides the collection of items and their operationalisation, the visit date of every documented encounter between patient and physician should be reported. In addition, each registry must define, prior to its start, those diagnoses that shall be covered by the study.

DISCUSSION
We present the first consensus-based core data set for pregnancy registries in rheumatology. The comprehensive list of 51 main items should be uniformly collected by all pregnancy registries in rheumatology to ensure homogeneity and comparability of data and to enable joint utilisation of different data sources.

To date, no such recommendations for pregnancy registries in rheumatology are available even though the need has been highlighted previously. In the absence of common standards, published pregnancy studies in rheumatology are highly heterogeneous, leading to partly controversial results or non-comparable information. In 2008, Schaefer et al summarised the objectives of pregnancy studies based on data of Teratology Information Services (TIS) and explained how they document and evaluate drug effects on pregnancy. Although most of the variables are also essential for pregnancy registries in rheumatology, TIS are not tailored to patients with IRD. Since the chronic disease itself can affect the pregnancy and its outcomes, it is essential to collect specific information on the disease course of IRD by registries and observational cohorts.

Recently, Vinet et al compiled basic lists with variables to be collected by rheumatic pregnancy registries focusing on the most important information needed to answer questions about disease activity, medication use and pregnancy outcome. Many variables correspond to the herein proposed core set. However, this core set goes beyond the list of desirable information and makes recommendations on how and in what way the information should be collected in order to harmonise different data sources. In addition, the Task Force has summarised disease-specific parameters that are essential for assessing the course and severity of the IRD. Further differences can be found in methodological aspects. Vinet and colleagues followed an individual approach representing their (North American) views, while the core set is based on a structured consensus process following the methodology for EULAR recommendations. A variety of European experts in the field as well as patient representatives were involved. Registry holders and users were able to incorporate their experience into the different steps of the voting process, and the Task Force has taken the feasibility of implementing the core set in everyday clinical practice in different countries into account. International acceptance therefore can be expected to be high.

This EULAR endorsed core set represents clinically relevant and feasible parameters that are critical for scientific research, especially with a focus on multinational collaborations. The challenge of the stepwise consensus process was to select the most relevant items regarding maternal information and the rheumatic disease as well as pregnancy and neonatal outcomes. This explains the inclusion of 51 items, which is—in comparison to other core sets in rheumatology or core sets with relation to maternal and new-born’s health—quite an extensive list.

The core set is a compromise between scientific purposes and research interests on the one hand and the feasibility for rheumatologists and other physicians or study nurses that document data from daily care on the other hand. We are for example aware of the importance of recording intrauterine growth restriction (IUGR) to differentiate between infants born small for gestational age (SGA) into those with a steady foetal development in rather lower percentiles of the growth curves versus those foetuses that first develop normally and then experience a sudden growth disturbance. However, we presume that information on IUGR may either be not available for many pregnancies or—since IUGR and SGA are often used interchangeably—their

![Table 2: Core areas for the core data set for pregnancy registries in rheumatology, IRD, inflammatory rheumatic disease.](image-url)
Table 2  Main items of the final core data set for pregnancy registries in rheumatology and their operationalisation and instruments for assessment

| No. | Main items                                      | Operationalisation/instruments for assessment                      |
|-----|------------------------------------------------|-------------------------------------------------------------------|
| Maternal information                                      |                                                                   |
| 1   | Age                                            | Date of birth or month/year of birth                              |
| 2   | Height                                         | cm                                                                |
| 3   | Weight before (or in early) pregnancy          | kg                                                                |
| 4   | Educational level                              | Highest educational level according to national standards or total years of completed education |
| 5   | Alcohol consumption during pregnancy           | Categorisation: yes/no                                           |
| 6   | Smoking during pregnancy                       | Categorisation: yes/no                                           |
| IRD disease characteristics                                 |                                                                   |
| 7   | IRD diagnosis                                  | Physician reported clinical diagnosis*                           |
| 8   | Classification criteria                        | Indication, which criteria are fulfilled                         |
| 9   | Disease duration                               | Month/year or year of diagnosis                                  |
| 10  | Physician reported IRD severity                | NRS or VAS                                                        |
| 11  | Auto-antibodies†                               | See additional recommendations (table 3)                         |
| 12  | Physician reported flares                      | Assessment of (1) yes/no; (2) number of flares                   |
| 13  | Physician reported disease activity            | NRS or VAS                                                        |
| 14  | Disease activity by score†                     | See additional recommendations (table 3)                         |
| 15  | C reactive protein                             | eg, mg/L                                                          |
| 16  | Patient reported disease activity              | NRS or VAS                                                        |
| 17  | Patient reported global health                 | NRS or VAS                                                        |
| Prevalent comorbidities                                    |                                                                   |
| 18  | Selected prevalent comorbidities              | Yes/no assessment of: (1) antiphospholipid syndrome, (2) diabetes mellitus, (3) arterial hypertension, (4) renal disease, (5) previous thromboembolic events |
| Pregnancy                                                  |                                                                   |
| 19  | Gravidity                                      | Number                                                            |
| 20  | Parity                                         | Number                                                            |
| 21  | Outcome of previous pregnancy(ies)            | Categorised into foetal death (including pregnancy loss and stillbirths/live birth; assessment of (1) number of foetal deaths and live births; (2) gestational age |
| 22  | Preterm birth(s)                              | Number                                                            |
| 23  | Neonatal death(s)                             | Number                                                            |
| 24  | Congenital malformations                      | Free text                                                         |
| 25  | Hypertensive pregnancy disorders              | Yes/no assessment of: pre-eclampsia, eclampsia, HELLP syndrome    |
| Course of current pregnancy                                |                                                                   |
| 26  | Planned pregnancy                             | Yes/No                                                            |
| 27  | Assisted reproduction                         | Yes/No                                                            |
| 28  | Estimated date of conception                   | Day/Month/Year                                                    |

Table 2  Continued

| No. | Main items                                      | Operationalisation/instruments for assessment                      |
|-----|------------------------------------------------|-------------------------------------------------------------------|
| 29  | Singleton*/-multiple pregnancy                 | Number of foetuses                                                |
| 30  | Adverse events of interest                     | (1) Yes/no assessment of non-serious and serious events of: (a) gestational hypertension, (b) pre-eclampsia, eclampsia, HELLP syndrome, (c) gestational diabetes, (d) thromboembolic events; (2) date of the beginning of the event; (3) indication if the event has led to hospitalisation or death* |
| 31  | Other serious adverse events                   | Assessment of (1) the kind of event as free text; (2) date of the beginning of the event; (3) indication if the event has led to hospitalisation or death* |
| 32  | Elective termination                           | Assessment of (1) yes/no; (2) gestational age; (3) reasons for termination categorised into (a) termination due to malformation, (b) termination due to other reasons |
| 33  | Foetal death                                   | Including pregnancy loss and stillbirths; assessment of (1) yes/no; (2) gestational age (weeks) at diagnosis |
| 34  | Live birth                                     | Yes/No                                                            |
| 35  | Gestational age at delivery                    | In weeks and days                                                  |
| 36  | Preterm premature rupture of membranes         | Yes/No                                                            |
| 37  | Mode of delivery                               | (1) Categorised into spontaneous vaginal delivery/operative vaginal delivery/caesarean section (CS)/mode of delivery not specified, and in case of CS (2) reasons categorised into: elective CS/foetal reasons/maternal reasons/ combined foetal and maternal reasons/unknown reasons |
| 38  | Birth weight                                   | In kilogram with two decimal digits or gram                       |
| 39  | Gender                                         | Categorisation: female/male/other                                 |
| 40  | Breast feeding                                 | Categorisation: yes, for at least 4 weeks after birth/no          |
| 41  | Congenital heart block                         | Yes/No                                                            |
| 42  | Congenital malformations                       | Free text                                                         |
| 43  | Neonatal serious adverse events during the first 28 days of life | Assessment of (1) the kind of event as free text; (2) date of the beginning of the event; (3) indication if the event has led to hospitalisation or death* |
| Treatment                                                  |                                                                   |
| 44  | DMARD use                                      | Assessment of (1) yes/no; (2) name§; (3) start/stop dates        |
| 45  | Oral glucocorticoid use                        | Yes/No                                                            |
| 46  | Use of potentially teratogenic medication      | Free text                                                         |
| IRD treatment during pregnancy and post partum             |                                                                   |
| 47  | DMARD use                                      | Assessment of (1) yes/no; (2) name§; (3) dose; (4) application intervals; (5) start/stop dates; (6) reasons for discontinuation |

*copyright.
different meaning may not always be clear. We therefore decided to exclude IUGR from the core set.

The supplemental material contains descriptions and definitions for all main items as far as this is possible. Even though it would be desirable to have uniform definitions for all items, this is not feasible for various reasons. Registries can only collect data within the framework of the health system and regulatory requirements of their country of origin and therefore, country-specific differences cannot be avoided."18 19 For a number of items, the reporting health professional has to rely on information that is provided by obstetricians, for example, the event of pre-eclampsia. Definition and classification systems however vary and can result in discrepancies of incidence rates.20 21

The period we were focused on for these recommendations was the time of pregnancy and the 28-day postpartum period (neonatal phase). The targeted patient population are patients with IRD. Since these recommendations shall be applicable to all IRDs, the final core set encompasses non-disease specific, generic items. Furthermore, for the five most prevalent IRDs, important laboratory markers and instruments to measure disease activity and damage have been defined. Of note, the core data set encompasses only the minimum items that have been classified as essential by experts in the field. It is up to each individual registry to add further items, to ask more details for an item and/or to use additional instruments or categories beyond those that are proposed within this core set.

Our proposed core set is on one side intended to serve as a basis for evolving registries to prioritise and facilitate data collection. On the other side, the core set can be used by existing observational studies and registries to focus their data quality management on those outcomes that were found to be of high importance to facilitate collaborative analyses with other registries. This will enable the growing number of (pregnancy) registries in Europe to perform joint analyses, allowing to explore relevant aspects in more detail and with robust data.

Collecting data in different countries by applying an internationally standardised protocol offers the chance to create the world’s largest source of information of pregnancies in women with IRD including drug safety. Encouraging and recruiting pregnant patients and collecting reliable data is the basis to fill current knowledge gaps and to guide IRD patients with the wish to have children in the future. Such a database can also serve as an information source for regulatory authorities and can help

---

**Table 2 Continued**

| No. | Main items | Operationalisation/instruments for assessment |
|-----|------------|-----------------------------------------------|
| 48  | Oral glucocorticoid use | Assessment of (1) yes/no; (2) dose; (3) application intervals; (4) start/stop dates |
| 49  | Intraarticular glucocorticoid use | Assessment of (1) yes/no; (2) date of application |
| 50  | NSAID use | Assessment of (1) yes/no; (2) name; (3) start/stop dates |

**Table 3 Additional items for selected diseases**

| Disease                               | Autoantibodies/laboratory markers                                      | Disease activity/damage scores                  |
|---------------------------------------|------------------------------------------------------------------------|------------------------------------------------|
| Rheumatoid arthritis                  | Anti-citrullinated protein antibody (ACP)                               | 28 SJC                                           |
|                                       | HLA-B27                                                                | 28 TJC, DAS28-CRP3                               |
| Spondyloarthitis                      |                                                                       | DAS28-CRP3                                      |
| Juvenile idiopathic arthritis         | Anti-citrullinated protein antibody (ACP)                               | 28 SJC                                           |
|                                       | HLA-B27                                                                | 28 TJC, DAS28-CRP3                               |
| Systemic lupus erythematosus          | Anti-phospholipid antibodies (aPL), in particular: anti-cardiolipin (aCL) antibodies, anti-beta-2-glycoprotein-I-antibodies, lupus anticoagulant (LA) | SLEPDAI (SLEDAI*)                                |
|                                       | Antinuclear antibodies (ANA)                                           | SLICC/ACR damage index                          |
|                                       |                                                                       | SLICC/ACR damage index                          |
| Other connective tissue diseases      | Anti-phospholipid antibodies (aPL), in particular: anti-cardiolipin (aCL) antibodies, anti-beta-2-glycoprotein-I-antibodies, lupus anticoagulant (LA) |                                                  |
|                                       | Extractable nuclear antigen (ENA) antibodies, in particular: anti-La/SSB antibodies, anti-SBP antibodies, anti-U1-ribonucleoprotein (RNP) antibodies |                                                  |
|                                       | Antinuclear antibodies (ANA)                                           |                                                  |
|                                       |                                                                       |                                                  |

*SLEDAI instead of SLEPDAI for postpartum disease activity.

ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAl, Bath Ankylosing Spondylitis Disease Activity Index; DAS28-CRP3, Disease Activity Score based on 28 tender and swollen joints and C reactive protein; SLICC/ACR Damage Index, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SJC, swollen joint count; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLEPDAI, Systemic Lupus Erythematosus in Pregnancy Disease Activity Index; TJC, tender joint count.

---
to establish research guidelines. With this core set, we hope to encourage other scientists to set up pregnancy registries and to collaborate in joint projects.

**Strengths and limitations**

The methodological strength of developing this core set is the application of robust methods with a stepwise consensus-based process involving multi-stakeholder groups, for example, experienced rheumatologists, epidemiologists, obstetricians, healthcare professionals and patients. The Delphi process is an established method for achieving consensus and has the advantage of maintaining the anonymity of participants. We had a low attrition rate with only one participant who did not complete both rounds. In all consensus steps, the participants were reminded that only those items that are both essentially important for joint research and feasible in daily clinical care, should be selected.

This core data set focuses on data collection during pregnancy including the outcome of pregnancy. This decision was made in order to achieve a minimal data set for the most important time period. However, information about the time before pregnancy and further observation of women and children after delivery is highly desirable in order to answer research questions like, for example, the development of pregnancy/abortion or the development of the child beyond 4 weeks of age. We therefore recommend to extend the observation of the child beyond the time frame addressed here in order to assess long-term outcomes concerning child development. This is a gap in the current literature and should be the focus of future collaborative studies with paediatricians.

**CONCLUSION**

This EULAR Task Force proposes a core data set with a minimum of items to be collected by pregnancy registries in rheumatology. Our aim was to facilitate collaborative research and joint data analyses. As the design of registries may vary considerably between countries and will be influenced by the different healthcare systems, this common data set was deliberately kept short and simple, concentrating on the most important information that is needed for meaningful joint analyses. We hope that this proposal will be useful when establishing new registries and also increase the willingness of rheumatologists, other healthcare professionals and patients to contribute to the registries and provide the necessary data.

**Author affiliations**

1Epidemiology and Health Care Research, German Rheumatism Research Center Berlin, Berlin, Germany
2Department of Rheumatology and Hiller Research Institute, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
3Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
4Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili di Brescia, Brescia, Italy
5Internal Medicine Department, Referral Center for Rare Autoimmune and Systemic Diseases, Hospital Cochin, Paris, France
6CRESS, INSERM, INRA, Université de Paris, Paris, France
7Department of Development and Regeneration KU, KU Leuven, Leuven, Belgium
8Medical Centre, Department of Rheumatology, Erasmus University Rotterdam, Rotterdam, Netherlands
9Department of Rheumatology, Immunology and Allergology, Inselspital University Hospital Bern, Bern, Switzerland
10Patient research partner, Berlin, Germany
11Rheumatology Department, Hospital Cochin, Paris, France
12U-1153, INSERM, University of Paris, Paris, France
13Obstetric Medicine Service, Queen Charlotte’s and Chelsea Hospital, London, UK
14Department of Women and Children’s Health, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
15Patient research partner, Duisburg, Germany
16Department of Obstetrics and Gynaecology, Inselspital University Hospital Bern, Bern, Switzerland
17Rheumatology Department, Hospital Universitario de la Princesa, Madrid, Spain
18Department of Malattie Rare, Immunologiche, Ematologiche ed Immunomotologiche. Centro di Ricerche di Immunopatologia e Documentazione su Malattie Rare (CIMID), Struttura Complessa a Direzione Universitaria di Immunologia Clinica, Ospedale Torino Nord Emergenza San G. Bosco ed Università di Torino, Torino, Italy
19Institut de Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
20Norwegian National Advisory Unit on Pregnancy and Rheumatic Diseases, Dept of Rheumatology, St Olavs Hospital University Hospital Trondheim, Trondheim, Norway

**Correction notice** This article has been corrected since it published Online First. The first author statement has been added.

**Twitter** Laura Andreoli @laurandreoli80, Diederik De Cock @DiederikDeCock, Anna Molto @annamolto, Catherine Nelson-Piercy @nelson_piercy and Sebastian Cruz Rodriguez-García @sdcrdrgonzlez

**Acknowledgements** The authors would like to thank all contributing experts who participated in the Delphi online survey: Peer Arjes; Sebnem Ataman; Irene Bultinck; Marion Couderc; Diana Dan; David d’Cruz; Jip de Vries; Thomas Dönner; Lene Dreyer; Aline Frazier; Ruth Fritsch-Stork; James Galloway; Ian Giles; Cornelia Glaser; Gaele Guettrot-Imbert; Isabell Haase; Karin Hellgren; Jörg Henes; Merete Hetland; Kimmy Hyrich; Synve Kalsstad; Emese Kiss; Estibalitz Lazaro; Véronique le Guern; Hanns-Martin Lorenz; Juan Antonio Martínez López; Monika Oestensen; Øyvind Palm; Jose Maria Pego-Reigosa; Antonia Puchner; Klara Rosta; Guillermo Ruiz-Irazoza; Christof Schaefer; Matthias Schneider; Carina Skorpen; Susanna Spåhlöf-Mestekemper; Christof Specker; Tone Starsteh Moksnes; Bjerg Tilde Svanes Fevang; Antonio Szanto; Gabriella Szucs; Tunde Tarr; Angela Tincani; Ines von Mühlen; Anne Voss; Corinna Weber-Schoendorff; Jakub Zavada.

**Collaborators** Peer Arjes; Sebnem Ataman; Irene Bultinck; Marion Couderc; Diana Dan; David d’Cruz; Jip de Vries; Thomas Dönner; Lene Dreyer; Aline Frazier; Ruth Fritsch-Stork; James Galloway; Ian Giles; Cornelia Glaser; Gaele Guettrot-Imbert; Isabell Haase; Karin Hellgren; Jörg Henes; Merete Hetland; Kimmy Hyrich; Synve Kalsstad; Emese Kiss; Estibalitz Lazaro; Véronique le Guern; Hanns-Martin Lorenz; Juan Antonio Martínez López; Monika Oestensen; Øyvind Palm; Jose Maria Pego-Reigosa; Antonia Puchner; Klara Rosta; Guillermo Ruiz-Irazoza; Christof Schaefer; Matthias Schneider; Carina Skorpen; Susanna Spåhlöf-Mestekemper; Christof Specker; Tone Starsteh Moksnes; Bjerg Tilde Svanes Fevang; Antonio Szanto; Gabriella Szucs; Tunde Tarr; Angela Tincani; Ines von Mühlen; Anne Voss; Corinna Weber-Schoendorff; Jakub Zavada.

**Contributors** All authors listed fulfilled authorship criteria. They have contributed to the task force and have been engaged in the design of the work, attended meetings, were involved in drafting the manuscript and approved the final version.

**Funding** This work was supported by EULAR and received a research grant from FOREUM Foundation in rheumatology.

**Competing interests** AM: speaker/consultant fees: Abbvie, BMS, MSD, Novartis, Pfizer, UCB; unrestricted grants: Pfizer and UCBAS; speaker fees: Abbvie, BMS, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis. AN: speaker fees: Pfizer. CM: consultancy fees from Pfizer. CR: consulting fees from UCB and Alliance Pharma. Speaker fees from UCB, Alliance Pharma, Alexion, Sanofi, Falk, Janssen, DCC: none. DG: none. FF: consultant for UCB, GSK, Roche. Speakers bureau: UCB, GSK. Research grants from UCB: speaker/consultant fees: GSK, Novartis, UCB, Eli Lilly, INOVA Diagnostics/Werfen Group. LR: none. MW: none. NC: none. D: no personal fees. Research grants from UCB/BD: received an unrestricted research grant from UCB Pharma BV and from the Dutch Arthritis Association a non-commercial fund raising organisation. RFB: speaker/consultant fees: Abbvie, Biogen, BMS, Celgene, Chugai, GSK, Janssen, Lilly, Medac, MSD, Novartis, Roche, UCBRO: None. SCR: G: speaker fees from Sanofi, MSD, UCB, Novartis and Janssen. SS: none. YM: lecture honoraria from Pfizer.

**Patient and public involvement** Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

**Patient consent for publication** Not required.

**Ethics approval** Full information about the study was given when inviting potential participants via email as well as on the website of the Delphi survey. Prerequisite for participation in the survey was a registration in the Delphi Manager system, which was considered to imply consent.

**Provenance and peer review** Not commissioned; externally peer reviewed.
Open access  This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID IDs
- Yvette Meissner http://orcid.org/0000-0003-0147-4112
- Laura Andreoli http://orcid.org/0000-0002-9107-3218
- Nathalie Costedoat-Chalumeau http://orcid.org/0000-0002-1555-9021
- Anna Molto http://orcid.org/0000-0003-2246-1986
- Sébastien Cruz Rodríguez-García http://orcid.org/0000-0002-7773-151X
- Savino Sciascia http://orcid.org/0000-0003-1266-9441
- Anja Strangfeld http://orcid.org/0000-0002-6233-022X

REFERENCES

1. Götestam Skorpen C, Hoeltenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. *Ann Rheum Dis* 2016;75:795–810.
2. Meissner Y, Strangfeld A, Costedoat-Chalumeau N, et al. European Network of Pregnancy Registers in Rheumatology (EuNeP)—an overview of procedures and data collection. *Arthritis Res Ther* 2019;21:241.
3. Radner H, Chatzidionysiou K, Nikolophorou E, et al. 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. *Ann Rheum Dis* 2018;77:476–9.
4. McCann LJ, Pilkington CA, Huber AM, et al. Development of a consensus core dataset in juvenile dermatomyositis for clinical use to research. *Ann Rheum Dis* 2018;77:241–50.
5. Ehlers L, Askling J, Bijlsma HW, et al. 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. *Ann Rheum Dis* 2019;78:1160–6.
6. Chatzidionysiou K, Hetland ML, Frisell T, et al. Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. *RMD Open* 2018;4:e000655.
7. van der Heijde D, Aletaha D, Camona L, et al. 2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. *Ann Rheum Dis* 2015;74:8–13.
8. Kirkham JJ, Davis K, Altman DG, et al. Core outcome Set-STAndards for development: the COS-STAD recommendations. *PloS Med* 2017;14:e1002447.
9. Guyatt GH, Oxman AD, Vist GE, et al. Grade: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6.
10. Boers M, Kirwan JR, Tugwell P, et al. The OMERACT Handbook, 2018.
11. Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC). Report to Secretary, health and human services Congress, 2018. Available: https://www.nichd.nih.gov/sites/default/files/2018-09/PRGLAC_Report.pdf [Accessed 16/11/18].
12. Giovannopoulou E, Gkasdaris G, Kapetanakis S, et al. And pregnancy: a literature review. *Curr Rheumatol Rev* 2017;13:162–9.
13. Andreoli L, Gerardi MC, Fernandezes M, et al. Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. *Autoimmun Rev* 2019;18:164–76.
14. Schaefer C, Omo Y, Clement M, et al. Using observational cohort data for studying drug effects on pregnancy outcome—methodological considerations. *Reprod Toxicol* 2008;26:36–41.
15. Östensen M, Andreoli L, Brucato A, et al. State of the art: reproduction and pregnancy in rheumatic diseases. *Autoimmun Rev* 2015;14:376–86.
16. Vint E, Chakravarty EF, Closet ME. Power in numbers. *Rheumatology* 2015;57:v0–7.
17. Duffy J, Ralph R, Gale C, et al. Core outcome sets in women’s and newborn health: a systematic review. *BJOG* 2017;124:1481–9.
18. Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. *Semin Arthritis Rheum* 2010;40:2–14.
19. Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. *Ann Rheum Dis* 2014;73:198–206.
20. Phipps E, Prasanna D, Birmi W, et al. Preeclampsia: updates in pathogenesis, definitions, and guidelines. *Clin J Am Soc Nephrol* 2016;11:1102–13.
21. Abalos E, Cuesta C, Grosso AL, et al. Global and regional estimates of preeclampsia and eclampsia: a systematic review. *Eur J Obstet Gynecol Reprod Biol* 2013;170:1–7.
22. Chiarotto A, Ostelo RW, Turk DC, et al. Core outcome sets for research and clinical practice. *Braz J Phys Ther* 2017;21:77–84.
23. Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider. *Trials* 2012;13:132.
24. Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. *PloS Med* 2011;8:e1000393.
25. ICH Guideline. Clinical safety data management: definitions and standards for expedited reporting E2A, 2020. Available: https://database.ich.org/sites/default/files/E2A_Guideline.pdf [Accessed 11/08/2020].